Citations

Clear

47 citation(s) found for "Scanlon, P D".

Timing and durability of response to erenumab in patients with chronic migraine
Tepper, Stewart J. , Lucas, Sylvia , Scanlon, James, Klatt, Jan , Chou, Denise E. , Wang, Andrea , Ashina, Messoud , Ashina, Messoud , Schwedt, Todd J. , Ailani, Jessica , Lima, Gabriel Paiva da Silva

Mayo Clinic

Headache: The Journal of Head and Face Pain | August 7, 2021 | Volume: 61 | Issue: 8 | Pages: 1255-1263

10.1111/head.14193 | PMID 34363708 Get It

Abstract Background Erenumab is a human anti‐calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM), specifically the onset and sustainability of monthly migraine day (MMD) response. Methods This is a post hoc analysis of a 12‐week, randomized, double‐blind, placebo‐controlled study of erenumab for migraine prevention in patients with CM (≥15 headache days/month, including ≥8 migraine days/month). Onset and sustainability were assessed according to MMD reduction from baseline, with the following response categories: responders (≥50% reduction), partial responders (≥30% and <50%), or nonresponders (<30%). Results Among the erenumab 140 mg group ( n = 187), 54.0% (101/187) achieved a response at any month during the study with a median time to onset of monthly response of 1 month. This improvement was maintained in most patients with continued treatment. An initial response was achieved at Month 1 by 28.3% (53/187) of patients; 69.8% (37/53) of whom maintained a response at Months 2 and 3. Although many patients responded early, some patients required longer treatment to achieve a response; 79.4% (27/34) of initial partial responders and 21.0% (21/100) of initial nonresponders subsequently achieved a response. Similar findings were observed for the erenumab 70mg group ( n = 188). Conclusion A majority of erenumab‐treated patients with CM who achieved an initial response at Month 1 sustained this benefit. Many patients responded later with continued treatment. Our data support recommendations to assess outcomes after ≥3 months of preventive treatment with erenumab in CM.
Assessment of Caucasian, Black, and Asian-American Individuals with Discordant Transfer Factor of the Lung for Carbon Monoxide (T LCO ) Using Two Common Reference Equations
Subat, Yosuf W., Scanlon, Paul D., Lim, Kaiser G. , Niven, Alexander S.

Mayo Clinic

TP37. TP037 PHYSIOLOGIC ASSESSMENT IN CHRONIC LUNG DISEASE | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A2177-A2177

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2177 Get It

Aerosol Generation During Methacholine Challenge Testing: Clinical Implications During the COVID-19 Pandemic
Subat, Yosuf W., Sajgalik, Pavol , Hainy, M., Torgerud, Keith D, Guntupalli, Siva Kamal, Scanlon, Paul D., Johnson, Bridgette, Helgeson, Scott A. , Johnston, J., Niven, Alexander S.

Mayo Clinic

TP117. TP117 COVID-19 PATHOPHYSIOLOGY AND MODELLING | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A4473-A4473

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4473 Get It

Risk of All-Cause Mortality During and After Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD): Post Hoc Analysis of the IMPACT Trial
Halpin, David , Hartley, Benjamin , Jain, Renu , Kaul, Viren , Kaye, Mitchell, Kraft, Monica , Mapel, Douglas W. , Midwinter, Dawn , Scanlon, Paul D., Singh, Diksha , Mammen, Manoj J. , Carr, Tara F. , Criner, Gerard J. , Dransfield, Mark T. , Han, MeiLan King , Singh, D., Wells, J. Michael , Wise, Robert A. , Lipson, David A.

Mayo Clinic

TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A2243-A2243

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2243 Get It

All-Cause Mortality by Subgroup in Patients with Chronic Obstructive Pulmonary Disease: Post Hoc Analysis of the IMPACT Trial
Halpin, David , Jain, Renu , Kaul, Viren , Kaye, Mitchell, Kraft, Monica , Mapel, Douglas W. , Midwinter, Dawn , Scanlon, PD, Mammen, Manoj J. , Carr, Tara F. , Criner, Gerard J. , Dransfield, Mark T. , Han, MeiLan King , Singh, Dave , Wells, J. Michael , Wise, Robert A. , Lipson, David A.

Mayo Clinic

TP40. TP040 COPD CLINICAL TRIALS AND THERAPIES | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A2241-A2241

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2241 Get It

What Produced the Gas in the Pleural Space?
Zhang, Zhihang , Scanlon, P.D., Scanlon, Paul D.

Mayo Clinic

D47. CRITICAL CARE CASE REPORTS: INFECTION AND SEPSIS II | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6938-A6938

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6938 Get It

Prevalence and Impact of Restrictive Lung Disease in Liver Transplant Candidates
Krowka, Michael J. , Forde, Kimberly A. , Mottram, Carl, Al‐Naamani, Nadine , Patel, Mamta, McCormick, Amber, Fallon, Michael B. , DuBrock, Hilary M. , Scanlon, Paul, Al-Naamani, Nadine , Krok, Karen , Scanlon, Paul , Kawut, Steven M.

Mayo Clinic

Liver Transplantation | May 12, 2020 | Volume: 26 | Issue: 8 | Pages: 989-999

10.1002/lt.25794 | PMID 32394590 Get It

We investigated the prevalence of spirometric restriction in liver transplantation (LT) candidates and the clinical impacts of restriction. We performed a cross‐sectional study within the Pulmonary Vascular Complications of Liver Disease 2 (PVCLD2) study, a multicenter prospective cohort study of patients being evaluated for LT. Patients with obstructive lung disease or missing spirometry or chest imaging were excluded. Patients with and without restriction, defined as a forced vital capacity (FVC) <70% predicted, were compared. Restriction prevalence was 18.4% (63/343). Higher Model for End‐Stage Liver Disease–sodium score (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.02‐1.11; P = 0.007), the presence of pleural effusions (OR, 3.59; 95% CI, 1.96‐6.58; P < 0.001), and a history of ascites (OR, 2.59; 95% CI, 1.26‐5.33; P = 0.01) were associated with the presence of restriction, though one‐third with restriction had neither pleural effusions nor ascites. In multivariate analysis, restriction was significantly and independently associated with lower 6‐minute walk distances (least squares mean, 342.0 [95% CI, 316.6‐367.4] m versus 395.7 [95% CI, 381.2‐410.2] m; P < 0.001), dyspnea (OR, 2.69; 95% CI, 1.46‐4.95; P = 0.002), and lower physical component summary Short Form 36 scores indicating worse quality of life (least squares mean, 34.1 [95% CI, 31.5‐36.7] versus 38.2 [95% CI, 36.6‐39.7]; P = 0.004). Lower FVC percent predicted was associated with an increased risk of death (hazard ratio, 1.16; 95% CI, 1.04‐1.27 per 10‐point decrease in FVC percent predicted; P = 0.01). Restriction and abnormal lung function are common in LT candidates; can be present in the absence of an obvious cause, such as pleural effusions or ascites; and is associated with worse exercise capacity, quality of life, and survival.
A Study of Bedside Visual Art To Decrease Anxiety and Improve Pain and Mood in Cancer Patients: The Mayo Clinic Experience.
Wolanskyj, Alexandra P., Curry, Elizabeth A., Ehlers, Shawna L. , Eagle, Debra M., Colby, Colin , Bauer, Brent A. , Scanlon, Paul D., Larson, Dirk R.

Mayo Clinic

Blood | November 17, 2019 | Volume: 110 | Issue: 11 | Pages: 975-975

10.1182/blood.v110.11.975.975 Get It

Abstract Background: The treatment of cancer-related symptoms continues to represent a major challenge for health care providers. Traditional approaches often require pharmacologic interventions which have potential side effects. A wide variety of approaches using complementary and alternative medicine (including music therapy) have demonstrated some early benefit. The role of a visual art intervention on pain, anxiety and mood has not been studied to date. Patients and Methods: Our patient population consisted of 21 Hematology inpatients at the Mayo Clinic (19 women, 2 men with a median age of 53.4 years, [range19 to 73]), with the following hematological disorders: Acute Leukemia (n = 6); Lymphoma (n = 5); Multiple Myeloma (n = 5); and a variety of other malignant conditions (n =5). Patients and their families were invited to participate actively or passively (i.e. observe) in a 1 to1 visual art intervention, conducted by a trained artist educator using different forms of art media. Baseline assessments of pain, anxiety and mood were conducted just prior to the intervention using Visual Analog scales (VAS), the Spielberger State Trait Anxiety Inventory and the Positive and Negative Affect Schedule (PANAS) respectively. The same scales were administered immediately following completion of the art intervention. Results: Twenty of 21 patients completed the intervention, and all 20 patients actively participated. A significant improvement in positive mood scores (4.6 [95%CI: (1.7, 7.5)] or 14.6% change, p=0.003), decrease in negative mood scores (−3.4 [95%CI: (−0.7, −6.1)] or 18% change, p=0.016) and in anxiety scores (−9.2 [95%CI: (−14.2, −4.1)] or 21.6% change, p=0.001) were observed. Among the 14 patients who reported some pain (VAS>0) prior to the intervention, the mean VAS pain score improved significantly (−1.4 [95%CI: (−2.4, −0.3)] or 35.1% change, p=0.017). Universally all patients commented that they would participate in art-based interventions in the future Conclusions Bedside visual art interventions can decrease pain and anxiety, and improve mood in hospitalized hematological patients with cancer diagnoses. These intriguing findings warrant future placebo-controlled studies, and suggest that these alternative measures should be considered as an adjunct to conventional therapies in patients with cancer-related pain, and symptoms of anxiety and decreased mood.
Estrogen Metabolism in Portopulmonary Hypertension (POPH): A Case-Control Study
Krowka, Michael J. , Forde, Kimberly A. , Bull, Todd M., Bartolome, Sonja, Lin, Grace , Oh, Jae K. , Mottram, Carl, Scanlon, Paul D., Patel, M., Fallon, Michael B. , Al‐Naamani, Nadine , Heresi, Gustavo A. , Roberts, Kari E. , Hemnes, Anna R. , Krok, Karen , DuBrock, Hilary M. , Austin, Eric , Kawut, Steven M.

Mayo Clinic

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5097-A5097

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5097 Get It